The pharma major on November 9 reported an 85 per cent year-on-year growth in net profit at Rs 757.2 crore for the Julu-September quarter. Revenue from operations increased 25.8 per cent to Rs 7,219.4 crore compared to Rs 5,739.3 crore. US formulation sales, the company's largest segment accounting for 47 per cent of its total revenue, rose 35.7 per cent to Rs 3,385 crore, on the back of strong performance in generic injectables unit Eugia. Europe formulation sales grew 16.7 per cent to Rs 1,769 crore, contributing 24.5 per cent to Aurobindo's total revenue.